Pharmaceuticals News and Research

RSS

Takeda expands commercial platform in Israel

Takeda Pharmaceuticals International GmbH today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets.

18 Dec 2013

Glaxo to stop paying docs worldwide for drug advocacy

The pharmaceutical giant ended the practice in the U.S. in 2011.

18 Dec 2013

Innovation leads to faster drug therapies, increased understanding of proteins on microscopic level

Membrane proteins are the "gatekeepers" that allow information and molecules to pass into and out of a cell. Until recently, the microscopic study of these complex proteins has been restricted due to limitations of "force microscopes" that are available to researchers and the one-dimensional results these microscopes reveal.

17 Dec 2013

Moderate drinking may bolster our immune system and help fight off infection: Study

Medical science has known for years that people who drink moderate amounts of alcohol actually have a reduced risk of death. In general, they are healthier and have better cardiovascular function that those who don't drink alcohol at all.

17 Dec 2013

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

Researchers discover control mechanism that can trigger development of MDS

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.

17 Dec 2013

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg.

17 Dec 2013

First Edition: December 17, 2013

Today's headlines include reports about how the health law is viewed by immigrant populations.

17 Dec 2013

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

17 Dec 2013

European team experts to explore role of neighborhood in everyday lives of people with dementia

A European team of experts led by The University of Manchester will explore, investigate and evaluate the role of the neighbourhood in the everyday lives of people with dementia and their families in a new research project announced during the G8 dementia summit today (11 December).

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

First Edition: December 16, 2013

Today's headlines include findings from an Associated Press poll probing Americans thoughts about the health law.

16 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.

16 Dec 2013

RT Oncology and Express Scripts enter into pharmaceutical drug distribution agreement

RT Oncology Services Corporation ("RainTree"), the nation's leading community oncology alliance, and Express Scripts (NASDAQ: ESRX), the nation's leading pharmacy benefit manager, today announced that they have entered into an exclusive, three-year pharmaceutical drug distribution agreement.

16 Dec 2013

Pharmaceuticals News and Research

Takeda expands commercial platform in Israel

Glaxo to stop paying docs worldwide for drug advocacy

Innovation leads to faster drug therapies, increased understanding of proteins on microscopic level

Moderate drinking may bolster our immune system and help fight off infection: Study

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Researchers discover control mechanism that can trigger development of MDS

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

First Edition: December 17, 2013

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

European team experts to explore role of neighborhood in everyday lives of people with dementia

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

First Edition: December 16, 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

RT Oncology and Express Scripts enter into pharmaceutical drug distribution agreement

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence